Treatment-resistant depression (TRD) — the patient population failing two or more antidepressant trials representing 30% of major depression cases and the primary target for first-generation psychedelic therapies — creates the most commercially dynamic market segment, with the Psychedelic Medicine Market reflecting TRD as the premium growth commercial driver. The NIH...